NASDAQ · OMCL
Healthcare · Medical - Healthcare Information Services
$35.46
Down-$0.25 (-0.71%)
Updated Oct 7, 2026, 10:00 PM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · OMCL
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
OMCL closed at $35.46 after 21 trading sessions, up 4.66% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $34.95 | $35.56 | $34.2401 | $35.46 | 634.25K |
| Oct 5, 2026 | $33.07 | $34.72 | $33.07 | $34.64 | 397.67K |
| Oct 2, 2026 | $33.93 | $33.96 | $33.41 | $33.60 | 344.5K |
| Oct 1, 2026 | $34.02 | $34.265 | $33.18 | $33.44 | 449.43K |
| Sep 30, 2026 | $34.26 | $34.46 | $33.71 | $34.05 | 592.46K |
| Sep 29, 2026 | $33.88 | $34.38 | $33.305 | $34.31 | 573.46K |
| Sep 28, 2026 | $33.21 | $33.95 | $32.70 | $33.87 | 563.6K |
| Sep 25, 2026 | $33.05 | $33.73 | $32.625 | $33.66 | 508.7K |
| Sep 24, 2026 | $33.01 | $33.23 | $32.595 | $33.03 | 499.53K |
| Sep 23, 2026 | $33.17 | $33.58 | $32.4017 | $32.99 | 437.01K |
| Sep 22, 2026 | $32.86 | $33.47 | $32.72 | $33.17 | 547.22K |
| Sep 21, 2026 | $32.43 | $32.57 | $31.975 | $32.43 | 434.86K |
| Sep 18, 2026 | $32.49 | $32.62 | $32.04 | $32.23 | 937.25K |
| Sep 17, 2026 | $32.76 | $33.215 | $32.26 | $32.62 | 394.29K |
| Sep 16, 2026 | $32.79 | $33.165 | $32.20 | $32.43 | 439.35K |
| Sep 15, 2026 | $33.13 | $33.35 | $32.23 | $32.63 | 642.62K |
| Sep 14, 2026 | $33.23 | $33.63 | $32.905 | $33.51 | 395.75K |
| Sep 11, 2026 | $32.88 | $33.015 | $32.32 | $32.79 | 483.65K |
| Sep 10, 2026 | $33.26 | $33.37 | $32.12 | $32.25 | 534.3K |
| Sep 9, 2026 | $33.49 | $33.675 | $32.8301 | $33.64 | 467.95K |
| Sep 8, 2026 | $33.75 | $35.30 | $33.54 | $33.88 | 571.11K |
The latest Smart Investors Daily articles mentioning OMCL.
Company
Market Activity
Research & News
OMCL research
Company profile and research snapshot.
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 3, 2026 | Piper Sandler | Overweight | — |
| Jul 31, 2026 | Keybanc | Overweight | — |
| Jul 31, 2026 | Wells Fargo | Overweight | — |
| Apr 29, 2026 | Keybanc | Overweight | — |
| Apr 23, 2026 | Wells Fargo | Overweight | — |
Generated Oct 7, 2026, 7:12 PM
Omnicell (OMCL) gained a modest $0.13 (0.37%) today, reflecting steady investor interest in the healthcare technology sector. The slight uptick comes as the company is being benchmarked among healthcare IT providers in Q2 sector recaps, providing visibility into its competitive positioning.
Bottom line: OMCL's modest 0.37% gain reflects steady positioning within the healthcare IT provider sector but lacks strong near-term catalysts. Investors should watch for Q2 earnings results and any new contract announcements that could demonstrate the company's growth trajectory and competitive strength in an important healthcare software market.
Yahoo · Oct 5, 2026
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at healthcare technology for providers stocks, starting with Omnicell (NASDAQ:OMCL).
ChartMill · Sep 25, 2026
Robotics automation earnings preview: Teradyne, Cognex, Omnicell, UiPath face key tests as momentum leaders and value laggards report.
Yahoo · Sep 22, 2026
Omnicell trades around US$33.17 after a mixed share price record, and the key issue now is whether that level lines up with the cash the business can generate over time. With the stock showing both long slumps and shorter rebounds, investors are left asking how closely the current market value tracks the company’s underlying cash flows. Over the past 5 years the share price has fallen 77.7%, which puts the spotlight firmly on whether the long term cash flow potential still supports today’s...
Yahoo · Sep 21, 2026
Omnicell has been treading water for the past six months, recording a small loss of 4.6% while holding steady at $32.74. The stock also fell short of the S&P 500’s 16.4% gain during that period.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning OMCL.
